Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.
Agenus has had a topsy-turvy month. Its share price fell off a cliff after the GlaxoSmithKline vaccine that uses its adjuvant failed a Phase III trial, only to rally this week on the back of news about its own clinical candidate.
Agenus has struck a deal to raise about $6.5 million from institutional backers in a direct offering of common stock and warrants. The financing was announced a day after the Lexington, MA-based biotech company revealed that patients with glioblastoma multiforme, a cancer which attacks the brain, who took its experimental vaccine lived more than twice as long without their cancer getting worse than those on the standard of care.
Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.
It's been a busy week or two for GlaxoSmithKline ($GSK)--the company has extended its agreement with Agenus ($AGEN), submitted two vaccines for approval and created a joint venture.
Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...
Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The
Now that Provenge and Yervoy have been approved, specialists are keying in on a new generation of immunotherapies that promise to change the standard of care for cancer. As Stephen Hodi, director of